A neural signature of metabolic syndrome

Eithan Kotkowski1,2 | Larry R. Price3 | Crystal Franklin1 | Maximino Salazar1 | Mary Woolsey1 | Ralph A. DeFronzo4,5 | John Blangero6 | David C. Glahn7,8 | Peter T. Fox1,2

1Research Imaging Institute, University of Texas Health Science Center at San Antonio, San Antonio, Texas
2Department of Radiology, University of Texas Health Science Center at San Antonio, San Antonio, TX
3Methodology, Measurement and Statistical Analysis Center, Texas State University, San Marcos, Texas
4Texas Diabetes Institute, San Antonio, Texas
5Diabetes Research Unit and Diabetes Division, University of Texas Health Science Center at San Antonio, San Antonio, Texas
6Genomics Computing Center, South Texas Diabetes and Obesity Institute, University of Texas Rio Grande Valley, Brownsville, Texas
7Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut
8Olin Neuropsychiatry Research Center, Institute of Living, Hartford Hospital, Hartford, Connecticut

Correspondence
Eithan Kotkowski and Peter T. Fox, Research Imaging Institute, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr., San Antonio, TX 78229.
Email: kotkowski@uthscsa.edu; fox@uthscsa.edu

Funding information
National Center for Advancing Translational Sciences, Grant/Award Number: T1L1TR002647-01; National Institute of Mental Health, Grant/Award Number: R01MH074457-1151; National Institutes of Health, Grant/Award Number: T32GM113898

Abstract
That metabolic syndrome (MetS) is associated with age-related cognitive decline is well established. The neurobiological changes underlying these cognitive deficits, however, are not well understood. The goal of this study was to determine whether MetS is associated with regional differences in gray-matter volume (GMV) using a cross-sectional, between-group contrast design in a large, ethnically homogenous sample. T1-weighted MRIs were sampled from the genetics of brain structure (GOBS) data archive for 208 Mexican-American participants: 104 participants met or exceeded standard criteria for MetS and 104 participants were age- and sex-matched metabolically healthy controls. Participants ranged in age from 18 to 74 years (37.3 ± 13.2 years, 56.7% female). Images were analyzed in a whole-brain, voxel-wise manner using voxel-based morphometry (VBM). Three contrast analyses were performed, a whole sample analysis of all 208 participants, and two post hoc half-sample analyses split by age along the median (35.5 years). Significant associations between MetS and decreased GMV were observed in multiple, spatially discrete brain regions including the posterior cerebellum, brainstem, orbitofrontal cortex, bilateral caudate nuclei, right parahippocampus, right amygdala, right insula, lingual gyrus, and right superior temporal gyrus. Age, as shown in the post hoc analyses, was demonstrated to be a significant covariate. A further functional interpretation of the structures exhibiting lower GMV in MetS reflected a significant involvement in reward perception, emotional valence, and reasoning. Additional studies are needed to characterize the influence of MetS’s individual clinical components on brain structure and to explore the bidirectional association between GMV and MetS.

KEYWORDS
genetics of brain structure, GOBS, gray matter volume, hypercholesterolemia, hyperglycemia, hypertension, hypertriglyceridemia, insulin resistance, insulin resistance syndrome, metabolic syndrome, MetS, Mexican-American, neuroimaging, obesity, T2DM, Type II diabetes mellitus, VBM, voxel-based morphometry, waist circumference

1 INTRODUCTION
Metabolic syndrome (MetS), also commonly known as the insulin resistance syndrome, is a cluster of physiological abnormalities associated with the development of cardiovascular disease (CVD). Type 2 diabetes mellitus (T2DM) and early death (Reaven, 1988). It typically comprises a combination of the following: central obesity measured as waist circumference (WC), elevated triglycerides (TG), reduced levels of high-density lipoprotein (HDL) cholesterol, increased fasting plasma glucose (FPG), and elevated blood pressure (BP; Grundy et al.,
Neuroimaging is an effective method for investigating the neurobiological correlates of cognitive decline in a human population with MetS. Comorbidities of MetS, namely obesity, insulin resistance, and T2DM, have been studied extensively using functional imaging (Byrne & Wild, 2011). Early positron emission tomography (PET) studies comparing insulin resistant subjects with normal controls, reported decreased gray matter glucose uptake in the dopaminergic reward circuit (amygdalae, hippocampi, and orbitofrontal cortex) and increased uptake in the striatum (nucleus accumbens, caudate, and putamen), insula and anterior cingulate (Anthony et al., 2006). Task-activation fMRI studies (food picture, smell, and taste paradigms) have also shown that glucose infusion is associated with discrete brain activation patterns and prandial satiety, correlating with the brain’s reward network (Huerta, Sarkar, Duong, Laird, & Fox, 2014; Michaud, Vainik, Garcia-Garcia, & Dagher, 2017).

Voxel-based morphometry (VBM), is a widely-accepted research technique employed to identify subtle, disease-related structural changes that cannot be easily inferred through region-specific or global gray matter volumetric analyses. VBM achieves this via group-averaging and registration to a standard brain space comparing gray matter densities between cases and controls. This method is optimal for identifying disease-specific atrophy patterns computed in a univariate, voxel-wise manner (Ashburner & Friston, 2000). In the literature, we know of only one other study that has looked at cortical thickness and subcortical volume changes (using ANCOVA instead of VBM with n = 86) explicitly in individuals with MetS (Song et al., 2014). However, only five VBM studies (with n ranging from 32 to 54) have investigated the neuroanatomical effects of T2DM (Wu, Lin, Zhang, & Wu, 2017). Other VBM studies have emphasized the GMV effects of MetS’s comorbidities, such as the combined effects of T2DM and hypertension (Tchistiakova et al., 2014) and obesity (Masouleh et al., 2016). Allostatic load, the accumulated multisystem physiological response to chronic stress that strongly correlates with MetS has also been studied using VBM as a predictor of stroke, diabetes, and neuroanatomical integrity (Zsoldos et al., 2018).

For this retrospective study, we utilized previously acquired neuroimaging data from a homogenous Mexican-American cohort comprising an extended-pedigree imaging dataset known as the Genetics of Brain Structure (GOBS) image archive of San Antonio, TX. In this dataset, participants were recruited at random from the San Antonio community as a measure to minimize selection bias. This archive presented a unique opportunity to study the neurobiological effects of MetS because of the population’s increased propensity, both biological and environmental, to develop MetS and its comorbidities. The sample is large enough to conduct a statistically powerful analysis, and includes a wide range of relevant data.

Participants were divided into two groups, randomly matched MetS and metabolically healthy controls (hereafter also referred to as “controls”), who differed only in metabolic status while controlling for age and sex. VBM was subsequently used to identify GMV differences between groups. After initial analysis, the large group was further subdivided in two post hoc analyses of “young” and “old” half samples to assess age-related effects. Lastly, BrainMap®, an imaging archive designed for meta-analysis and meta-analytic data interpretation, was
used to interpret behavioral, paradigm class, and disease covariates from our results (Lancaster et al., 2012).

We hypothesized: (a) that a group contrast VBM analysis will reveal discrete MetS-specific GMV differences; (b) that the patterns observed would recapitulate regions implicated in AD pathology (per the CNS insulin resistance hypothesis); and, (c) that applying meta-analytic interpretive tools (BrainMap.org) to the VBM-derived regional deficits would confirm a cognitive signature corresponding to cognitive deficits previously reported in MetS.

2 | MATERIALS AND METHODS

2.1 | Participants

The goal of the GOBS dataset is to localize, identify, and characterize genes/quantitative trait loci associated with variations in brain structure and function (Winkler et al., 2010). The GOBS dataset has been acquired in three blocks of acquisitions, corresponding to the original grant and two renewals. In the original block of acquisitions, the emphasis was almost entirely on imaging and cognitive/behavioral phenotypes with BMI and health history being the only phenotypes referable to metabolic syndrome. In the second block of acquisitions, blood chemistries (including fasting plasma glucose), a lipid panel, and waist circumference (WC) were added. In the third block of acquisitions, BP was added. Participants in the present analysis were drawn only from acquisition Blocks 2 and 3. In all three blocks of acquisition, participants were drawn from the same extended-pedigree, Mexican-American families. At the time this study was conducted, a total of 1,911 individuals were enlisted in the GOBS dataset.

In acquisition Blocks 2 and 3, neuroanatomic, neurocognitive, and biometric phenotypes were obtained on each participant. Participants were subjected to the standardized Composite International Diagnostic Interview (CIDI; Kessler, Andrews, Mroczek, Ustun, & Wittchen, 1998) and the Mini-International Neuropsychiatric Interview (MINI-Plus) for DSM-IV and ICD-10 psychiatric disorders (Sheehan et al., 1998). Blood samples were collected after a 12-hr fast and processed in order to obtain blood chemistry and blood lipid data, such as triglycerides, cholesterol, and fasting plasma glucose.

Acquiring BP values did not become standard protocol until acquisition Block 3. This left ~70% of the eligible participants from the GOBS cohort without measured BP. However, from the 835 participants with all pertinent imaging and lipid data (Figure 1), a total of 356 (42.6%) had available BP data. Excluding participants with no BP values, but who nonetheless had all other pertinent data, would have left us with a small and underpowered cohort. We overcame this obstacle by diagnosing our data as missing at random (MAR), indicating that there is a systematic relationship between observed data (the 42.6% of BP data available) and missing values (the 57.4% of missing BP data). BP can therefore be imputed from available observed BP data and other observed variables known to correlate with BP (e.g., age, sex, height, weight, WC, fasting plasma glucose, triglycerides, blood urea nitrogen, creatinine, sodium, potassium, chloride, calcium, smoking status, total cholesterol, high density, low density, and very low-density lipoprotein cholesterol, and previous diagnosis of hypertension; Little & Rubin, 2002). Missing BP values were thus imputed using a well-validated model-based full information maximum likelihood estimation from the aforementioned observed variables (Enders, 2010).

As a cross-check we evaluated whether the MAR assumption was tenable and performed sensitivity analysis under the missing not at random (MNAR) assumption. We employed the fully conditional specification for multiple imputation to impute BP values for participants in the study group based on observed values of participants not included in the study group (Ratitch & O’Kelly, 2011). Using this test of model sensitivity, we were able to discern whether differences existed between groups on BP values assuming the MAR versus MNAR assumption. The results of the sensitivity analysis yielded the same conclusions as those observed under MAR.

FIGURE 1 Participant selection pipeline from the original GOBS dataset applying MetS criteria scores based on a composite of the International Diabetes Federation (IDF) and National Cholesterol Education Program-Adult Treatment Plan III (NCEP-ATP III). Criteria for metabolically healthy control group was determined by including participants with a composite MetS score of ≤1.5. Criteria for MetS case group was determined by including participants fulfilling the WC criteria of the IDF and achieving a MetS score of ≥3.0. A few borderline individuals (3 controls and 6 MetS) were added to provide age- and sex-matched symmetry in the final analysis.
2.2 | Image acquisition

MRI acquisition was carried out on a 3T Siemens Tim MRI scanner at the University of Texas Health Science Center at San Antonio’s Research Imaging Institute. An 8-element high-resolution phase array head coil equipped with foam padding was employed to comfortably restrict head motion. A standard localizer image was obtained for each participant for determining head placement, followed by a standard shim sequence. Seven high quality T1-weighted 3D structural images were collected per participant via a TurboFLASH sequence with an adiabatic inversion recovery pulse (TR = 3.04 ms, TE = 2000 ms, TI = 795 ms, flip angle = 8°, NEX = 6) optimized to achieve a gray/white contrast of ~25% with signal to noise ratio of 25. Each image contained 0.8 mm³ isotropic voxels and a 20 cm field of view. Scan time per participant totaled 60 min. Each of the seven MPRAGE T1-weighted images was motion corrected and all were subsequently averaged to generate a single high-resolution anatomical image per participant (Kochunov et al., 2006).

2.3 | Study sample

Of the 1,911 total participants in the GOBS cohort, we excluded 519 participants who were lacking successfully acquired T1-weighted MRI scans, and 557 participants from the first acquisition phase who were lacking full biometric data such as blood lipids and WC necessary to establish a MetS diagnosis. Upon reviewing data obtained from CIDI and MINI-Plus evaluations, we then excluded 122 participants with past medical histories of stroke, neurosurgery, neurological diseases, or Axis I psychiatric diagnoses (e.g., schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, and so on). Our final sample of neurologically and psychiatrically healthy individuals who met basic imaging, psychiatric, biometric, and metabolic criteria totaled 713 participants.

We applied both the National Cholesterol Education Program Adult Treatment Plan III (NCEP-ATP III) and the International Diabetes Federation (IDF) criteria (Figure 1) to the selection of metabolically healthy and MetS participants (Eckel & Cornier, 2014). The NCEP-ATP III defines MetS as patients meeting at least three of the following five criteria: 1. central obesity measured by WC (≥102 cm in men, ≥ 88 cm in women), 2. raised TGs (≥ 150 mg/dL), 3. reduced HDL cholesterol (<40 mg/dL in men, < 50 mg/dL in women), 4. raised FPG (≥ 110 mg/dL), and 5. elevated BP (≥ 130 mmHg systolic or ≥ 85 mmHg diastolic) and/or diagnosis of HTN (Eckel & Cornier, 2014). Similarly, the IDF defines MetS as a disease in which patients must exhibit central obesity (WC of ≥94 cm for men, ≥ 80 cm for women), along with at least two of the following four criteria: 1. raised TGs (>150 mg/dL) and/or taking medication for hypertriglyceridemia, 2. reduced HDL cholesterol (<40 mg/dL in men, < 50 mg/dL in women) and/or taking medication for hypercholesterolemia, 3. raised BP (>130 mmHg systolic or >85 mmHg diastolic) and/or taking medication for hypertension, and 4. raised FPG (>100 mg/dL) and having a diagnosis of T2DM (Grundy et al., 2005).

A score of 0–5 was generated for each of the 713 eligible participants based on how many components (WC, TG, HDL, FPG, and BP) met the MetS criteria for NCEP-ATP III and IDF respectively (Tables 1 and 2). For example, a male participant with a WC of 98 cm would receive a score of 1 for WC under the IDF criteria, but receive a score of 0 for WC under the NCEP-ATP III criteria. Both the IDF and NCEP-ATP III scores were then averaged to give each participant a single composite MetS score based on both criteria. A score of 3 or greater would be considered indicative of MetS under the standards for both criteria.

Metabolically healthy controls were selected from the remaining 713 eligible participants if they had a composite MetS score of 1.5 or lower (n = 319) and MetS participants were selected if they had a composite MetS score of 3 or higher (n = 255). From the latter group, we further excluded MetS subjects who did not meet the IDF criteria for WC (n = 7). We then employed an algorithm that optimally and randomly age- and sex-matched the participants who met the study-specific criteria for controls and for MetS. A total of 101 controls (n = 44 males, n = 57 females; plus 3 borderline) and 98 MetS participants (n = 42 males, n = 56 females; plus 6 borderline) were matched successfully (Figure 1). We included borderline individuals to optimally configure the group-matching framework between age and sex that is required for a two-group difference general linear model analysis. Borderline control individuals had a composite score of 2. They did not meet the ≤1.5 cut-off, nor the IDF or NCEP-ATP III criteria for MetS. Similarly, borderline MetS individuals had a composite score of 2.5, meeting the IDF criteria for MetS, but not for NCEP-ATP III.

These criteria were derived in consultation with Dr. Ralph DeFronzo, director of the Texas Diabetes Institute and were considered the best accepted estimates to define two groups that are metabolically distinct as “healthy” and “MetS” (Miranda, DeFronzo, Califf, & Guyton, 2005). Particular emphasis was made on defining the MetS group as meeting at least the IDF criteria for WC. This emphasis is important because central obesity as measured by WC is an easily measurable biometric variable that closely correlates with insulin resistance (Simonson & Kendall, 2005).

2.4 | VBM and univariate analysis

T1 structural images were acquired retrospectively from the GOBS dataset. Freesurfer was used for initial processing with autorecon1 (motion correction, nonuniform intensity normalization, Talairach transform computation, intensity normalization, and skull stripping; Fischl, 2012). Brain-extracted data were then analyzed with FSL-VBM (Douaud et al., 2007), an optimized VBM protocol carried out with FSL tools (FMRIB Software Library; Good et al., 2001; Smith et al., 2004). Structural images were gray matter–segmented and nonlinearly registered to MNI-152 standard space (Andersson, Jenkinson, & Smith, 2007). The resulting images were averaged, flipped along the x-axis, and re-averaged to create a left-right symmetric, study-specific gray matter template. All native gray matter images were nonlinearly registered to this study-specific template and “modulated” to correct for local expansion (or contraction) due to the nonlinear component of the spatial transformation. The modulated gray matter images were smoothed with an isotropic Gaussian kernel (sigma = 3 mm).
To compare MetS versus metabolically healthy control group differences in GMV, a two-group difference (two-sample unpaired t-test) analysis using voxel-wise general linear modeling (GLM) was applied in a control vs. MetS contrast analysis involving all participants (n = 208) with "years of education" as a nuisance covariate. Two separate post hoc contrast analyses were subsequently conducted along age-defined half samples. We ran the GLM analysis with FSL’s Randomize, a nonparametric permutation-testing tool (10,000 permutations), that corrects for multiple comparisons across voxels. Significance was determined at the voxel level using a family-wise error (FWE) correction (p < .05). In VBM, the null hypothesis states that there is no difference in GMV between the groups being studied. The null hypothesis is refuted when statistical maps are generated exhibiting voxels, often clustered together, that overcome a predetermined and study-specific statistical threshold (e.g., FWE p05, in the case of the present study; Whitwell, 2009). We did not further correct for the total number of VBM’s performed (i.e., 3) since the post hoc age-defined half samples were independent of the large primary analysis.

The output comprised of threshold-free cluster enhancement (TFCE) based statistical parametric maps depicting locations of gray matter differences between MetS and metabolically healthy control groups. TFCE avoids the arbitrary definition of an initial cluster-forming threshold, as in cluster-based thresholding, by enhancing cluster-like structures while maintaining a voxel-wise approach (Smith & Nichols, 2009). The final results were overlaid onto the MNI-152 standard template. Maxima locations for the large 208-subject contrast were derived from the Talairach Daemon (Table 3; Lancaster et al., 2000). A summary of the VBM image analysis pipeline is shown in Figure 2.

### 2.5 Post hoc analysis on age effects

Two additional post hoc analyses involving the subdivided large group of 208 participants were performed using identical thresholds and permutations. In this analysis we divided participants by the median age (35.5 years) and grouped them into half samples termed "young" and "old." The "young" group included all participants with age ≤ 35 years (mean = 26.4 ± 4.6 years; range = 18–35 years); 52 metabolically healthy controls and 52 MetS participants. The "old" group included all participants with age ≥ 36 (mean = 48.1 ± 9.6 years; range = 36–74 years); 52 metabolically healthy controls and 52 MetS participants (Tables 1 and 2, Figure 3).

### 2.6 Behavior, paradigm class, and disease analyses

BrainMap is a neuroimaging database which, at the time of this study, contained 15,243 published functional imaging experiments (125,588
locations) from 3,261 peer-reviewed publications and 3,151 published VBM, or structural imaging experiments, (21,827 coordinates) from 994 peer-reviewed publications. BrainMap reports statistically significant results from the published, peer-reviewed neuroimaging literature in the form of standardized coordinates that report functional and structural effects (Fox, Lancaster, Laird, & Eickhoff, 2014). It allows investigators to perform robust meta-analyses from thousands of subjects, experiments, and paradigms using the standardized, coordinate-based \((x, y, z)\) mapping system. The results have been coupled to experimental and behavioral conditions in the functional task-driven database (Lancaster et al., 2012), and disease diagnoses in the structural VBM database (Vanasse et al., 2018).

BrainMap’s® Behavior and Paradigm Class analysis plugins are invaluable meta-data inference function tools that quantitatively characterize regions that are anatomically altered in MetS and show how these regions relate to healthy brain functions (Crossley et al., 2014; Smith et al., 2009). Using this method, we can test the hypothesis that negative behavioral effects of MetS—specifically concerning impairment of executive function, cognitive reasoning, and reward perception—can be at least partially explained by structural changes in the form of GMV loss (Crossley, Scott, Ellison-Wright, & Mechelli, 2015; Fox et al., 2014; Glahn et al., 2008). Similarly, BrainMap’s Disease Inference Function also uses meta-data inferencing to correlate GMV changes in MetS to neurodegenerative diseases present in the BrainMap VBM structural database (Kotkowski, Price, Fox, Vanasse, & Fox, 2018; Vanasse et al., 2018). We can use this function to independently quantify the degree of structural similarity between neurodegenerative diseases like AD and MetS using a z-score.

BrainMap’s software allows for behavior, paradigm class, and disease comparisons by imputing a 3D spatial region of interest known as a "mask." Masks in this study were generated by the VBM analyses and represent the regions of significant GMV reduction. The software allows us to compare regions derived in our study to behaviors and paradigm classes ascribed to a number of functional studies, or

### Table 2: Percentage of participants meeting MetS criteria by group

<table>
<thead>
<tr>
<th>Metabolic syndrome components</th>
<th>Total control</th>
<th>Total MetS</th>
<th>Young control</th>
<th>Young MetS</th>
<th>Old control</th>
<th>Old MetS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>International diabetes federation</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Waist circumference:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥96 cm in men, ≥80 cm in women</td>
<td>41.3%</td>
<td>100%</td>
<td>23.1%</td>
<td>100%</td>
<td>59.6%</td>
<td>100%</td>
</tr>
<tr>
<td>Triglycerides:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥150 mg/dL and/or HTG Rx</td>
<td>1.0%</td>
<td>93.3%</td>
<td>1.9%</td>
<td>94.2%</td>
<td>0%</td>
<td>92.3%</td>
</tr>
<tr>
<td>HDL cholesterol:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;40 mg/dL in men, &lt;50 mg/dL in women and/or HCL Rx</td>
<td>3.8%</td>
<td>94.2%</td>
<td>3.8%</td>
<td>90.4%</td>
<td>3.8%</td>
<td>98.1%</td>
</tr>
<tr>
<td>Fasting plasma glucose:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;100 mg/dL and/or T2DM dx</td>
<td>1.0%</td>
<td>60.6%</td>
<td>0%</td>
<td>38.5%</td>
<td>1.9%</td>
<td>78.8%</td>
</tr>
<tr>
<td>Blood pressure&lt;sup&gt;b&lt;/sup&gt;:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥130 mmHg systolic or ≥85 mmHg diastolic and/or HTN dx</td>
<td>13.5%</td>
<td>61.5%</td>
<td>11.5%</td>
<td>48.1%</td>
<td>15.4%</td>
<td>75.0%</td>
</tr>
<tr>
<td>Meet IDF criteria for MetS</td>
<td>0%</td>
<td>100%</td>
<td>0%</td>
<td>100%</td>
<td>0%</td>
<td>100%</td>
</tr>
<tr>
<td><strong>National cholesterol education program adult treatment plan III</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Waist circumference:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥102 cm in men, ≥88 cm in women</td>
<td>9.6%</td>
<td>92.3%</td>
<td>1.9%</td>
<td>90.4%</td>
<td>17.3%</td>
<td>94.2%</td>
</tr>
<tr>
<td>Triglycerides:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥150 mg/dL</td>
<td>1.0%</td>
<td>87.5%</td>
<td>1.9%</td>
<td>94.2%</td>
<td>0%</td>
<td>80.8%</td>
</tr>
<tr>
<td>HDL cholesterol:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;40 mg/dL in men, &lt;50 mg/dL in women</td>
<td>2.9%</td>
<td>83.7%</td>
<td>1.9%</td>
<td>88.5%</td>
<td>3.8%</td>
<td>78.8%</td>
</tr>
<tr>
<td>Fasting plasma glucose:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;110 mg/dL</td>
<td>0%</td>
<td>33.7%</td>
<td>0%</td>
<td>14.8%</td>
<td>0%</td>
<td>51.9%</td>
</tr>
<tr>
<td>Blood pressure&lt;sup&gt;b&lt;/sup&gt;:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥130 mmHg systolic or ≥85 mmHg diastolic and/or HTN dx</td>
<td>13.5%</td>
<td>61.5%</td>
<td>11.5%</td>
<td>48.1%</td>
<td>15.4%</td>
<td>75.0%</td>
</tr>
<tr>
<td>Meet NCEP-ATP III criteria for MetS</td>
<td>0%</td>
<td>87.5%</td>
<td>0%</td>
<td>90.4%</td>
<td>0%</td>
<td>84.6%</td>
</tr>
</tbody>
</table>

**Previously diagnosed comorbidities**

<table>
<thead>
<tr>
<th></th>
<th>Total control</th>
<th>Total MetS</th>
<th>Young control</th>
<th>Young MetS</th>
<th>Old control</th>
<th>Old MetS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertriglyceridemia</td>
<td>0%</td>
<td>21.2%</td>
<td>0%</td>
<td>3.8%</td>
<td>0%</td>
<td>38.5%</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>1.9%</td>
<td>33.7%</td>
<td>1.9%</td>
<td>11.5%</td>
<td>1.9%</td>
<td>55.8%</td>
</tr>
<tr>
<td>Type II diabetes mellitus</td>
<td>0%</td>
<td>31.7%</td>
<td>0%</td>
<td>13.5%</td>
<td>0%</td>
<td>50%</td>
</tr>
<tr>
<td>Hypertension</td>
<td>3.8%</td>
<td>35.6%</td>
<td>0%</td>
<td>17.3%</td>
<td>7.7%</td>
<td>53.8%</td>
</tr>
</tbody>
</table>

Abbreviations: Dx, previously diagnosed; HCL, hypercholesterolemia; HDL, high density lipoprotein cholesterol; HTG, hypertriglyceridemia; HTN, hypertension; IDF, International Diabetes Federation; NCEP-ATP III, National Cholesterol Education Program Adult Treatment Plan III; Rx, currently receiving treatment; T2DM, Type 2 diabetes mellitus.

<sup>b</sup>BP values obtained were generated in part by full-information maximum likelihood statistical modeling.
diseases in VBM studies, from across the BrainMap database. This is achieved by comparing our mask to a null reference of random spatial distribution. Z-scores are generated for observed-minus-expected values for each behavior sub-domain, or disease sub-domain in the case of VBM, with the operative threshold $z$-score of 3.0 as comparable to a group $p$-value of .05. This analysis has been previously validated in both the behavior domain and paradigm class analyses (Lancaster et al., 2012) and recently in disease class analyses (Kotkowski et al., 2018). Due to a lack of inclusion of the cerebellum and brainstem in the vast majority of task activation studies involving PET and fMRI within the BrainMap database, the cerebellum and brainstem regions were excluded from the ROI masks in this analysis.

### 3 | RESULTS

#### 3.1 | Mass univariate VBM contrast analysis

A VBM contrast analysis was performed to investigate regional GMV differences between age- and sex-matched metabolically healthy controls ($n = 104$) and individuals meeting the criteria for MetS ($n = 104$; see Tables 1 and 2, Figure 1). The most notable between-group differences were found in the following regions: the posterior cerebellum, brainstem, orbitofrontal cortex (aka ventromedial prefrontal cortex), bilateral caudate nuclei, right posterior insula, right amygdala, lingual gyrus, and superior temporal gyrus (Figure 3, Table 3).

#### 3.2 | Structural age differences

Age differences were observed when contrasting participants in the post hoc age-defined half-samples. The "young" participants contrast analysis ($\leq 35$ years) reported significantly lower GMV in the posterior cerebellum only (Figure 3, Table S1). Furthermore, the "old" participants contrast analysis ($\geq 36$ years) reported significantly lower GMV in a more diffuse pattern than the whole group analysis and involved a greater number of affected regions. The notable regions in the "old" group analysis included: the posterior cerebellum, brainstem, orbitofrontal cortex, caudate nuclei, right posterior insula, right amygdala, lingual gyrus, and superior temporal gyrus (Figure 3, Table S2).

### TABLE 3

<table>
<thead>
<tr>
<th>Cluster</th>
<th>Cluster size (voxels)</th>
<th>Foci: MNI coordinates</th>
<th>Max $t$-score within cluster</th>
<th>Cluster foci: MNI Daemon label</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brainstem</td>
<td>13,187</td>
<td>2, –28, –48</td>
<td>4.98</td>
<td>Pons</td>
</tr>
<tr>
<td>L. Cerebellum</td>
<td>28,818</td>
<td>–24, –62, –46</td>
<td>5.73</td>
<td>L. Crus I</td>
</tr>
<tr>
<td>R. Cerebellum</td>
<td>24,419</td>
<td>20, –66, –46</td>
<td>5.44</td>
<td>R. Cerebellar tonsil</td>
</tr>
<tr>
<td>Orbitofrontal cortex</td>
<td>9,175</td>
<td>4, 14, –24</td>
<td>5.66</td>
<td>R. Rectal gyrus (BA11)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12, 62, –22</td>
<td>3.90</td>
<td>R. Superior Frontal Gyrus (BA10)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12, 44, –28</td>
<td>4.14</td>
<td>R. Medial frontal gyrus (BA11)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>–6, 14, –28</td>
<td>4.68</td>
<td>R. Lateral gyrus</td>
</tr>
<tr>
<td></td>
<td></td>
<td>–12, 34, –32</td>
<td>3.64</td>
<td>L. Orbital gyrus (BA47)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>–2, 28, –30</td>
<td>4.49</td>
<td>R. Rectal gyrus (BA11)</td>
</tr>
<tr>
<td>L. Limbic lobe</td>
<td>891</td>
<td>–16, –28, –12</td>
<td>3.00</td>
<td>L. Parahippocampal gyrus</td>
</tr>
<tr>
<td>R. Limbic lobe</td>
<td>3,071</td>
<td>18, 2, –18</td>
<td>4.25</td>
<td>Subcallosal gyrus (BA34)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>27, –2, –16</td>
<td>3.60</td>
<td>R. Amygdala</td>
</tr>
<tr>
<td>R. insula</td>
<td>4,026</td>
<td>34, 0, –12</td>
<td>3.73</td>
<td>R. Claustrum</td>
</tr>
<tr>
<td></td>
<td></td>
<td>42, –2, –8</td>
<td>3.41</td>
<td>R. Insula</td>
</tr>
<tr>
<td>L. Caudate</td>
<td>2,752</td>
<td>–12, 16, 10</td>
<td>4.70</td>
<td>L. Caudate body</td>
</tr>
<tr>
<td>R. Caudate</td>
<td>4,054</td>
<td>8, 22, 8</td>
<td>4.59</td>
<td>R. Caudate body</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6, 14, 4</td>
<td>4.00</td>
<td>R. Caudate body</td>
</tr>
<tr>
<td>Cuneus</td>
<td>2,787</td>
<td>–4, –64, 8</td>
<td>3.51</td>
<td>L. Cuneus</td>
</tr>
<tr>
<td></td>
<td></td>
<td>–6, –84, 8</td>
<td>3.05</td>
<td>L. Lingual gyrus</td>
</tr>
<tr>
<td>R. Temporal lobe</td>
<td>2,444</td>
<td>70, –24, 0</td>
<td>4.15</td>
<td>R. Superior temporal gyrus (BA22)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>68, –12, –6</td>
<td>3.33</td>
<td>R. Middle temporal gyrus</td>
</tr>
<tr>
<td>Lingual gyrus</td>
<td>637</td>
<td>8, –98, 4</td>
<td>3.19</td>
<td>R. Lingual gyrus</td>
</tr>
</tbody>
</table>

Results are significant at FWE $p < .05$, corrected for multiple comparisons at the voxel level. Abbreviations: BA, Brodmann area; L., left; R., right.
3.3 BrainMap behavior, paradigm class, and disease meta-analysis

MetS-associated regions exhibiting decreased GMV in the cortex (not including the cerebellum and brainstem) from the whole sample ($n = 208$) were associated with cognitive reasoning ($z = 5.4$), emotional valence ($z = 5.4$), and reward paradigms ($z = 6.7$). These regions were also found to be similar in gray matter pathology to Huntington’s disease (HD; $z = 3.6$) and AD ($z = 3.0$; Figure 4). A $z$-score of $\geq 3.0$ is considered statistically significant using this method (Lancaster et al., 2012).

No statistically significant findings were reported for the “young” half-sample subgroup ($n = 104$). Cortical brain regions did not exhibit any significant GMV differences in this analysis. However, findings of significantly lower GMV in the posterior cerebellum were reported.

MetS-associated regions exhibiting decreased GMV in the cortex from the “old” half-sample subgroup ($n = 104$) were associated with cognitive reasoning ($z = 6.0$), fear modulation ($z = 3.7$), music composition ($z = 3.6$), audition perception ($z = 3.3$), reward paradigms ($z = 7.7$), face monitor/discrimination paradigms ($z = 4.3$), pitch monitor/discrimination paradigms ($z = 3.7$), and music comprehension paradigms ($z = 3.6$). These regions were also found to be similar in gray matter pathology to AD ($z = 4.9$), HD ($z = 4.5$), and schizophrenia ($z = 4.2$; Figure 4). Definitions for these terms can be found in Table S3.

4 DISCUSSION

Two of the three hypotheses put forward in the present study were supported by our findings. The first hypothesis, that a discrete pattern of GMV differences would be identified in individuals with MetS, was strongly confirmed. Specific GMV reductions were found in the cerebellum, brainstem, OFC, caudate, amygdala, insula, and superior temporal gyrus, among others. Additionally, age-related effects were observed in two separate post hoc young versus old analyses from the larger group sample, suggesting increased age-related effects influencing GMV between MetS participants and metabolically healthy controls. The second hypothesis—that patterns of GMV loss would recapitulate AD pathology—was weakly confirmed in the overall analysis. BrainMap’s disease inference function identified AD’s pattern of GMV changes as the neurodegenerative disease pattern most closely resembling our MetS VBM findings. This was especially noticeable in the “old” half-sample analysis. HD and schizophrenia were the other diseases exhibiting significant similarities in GMV loss with MetS. Importantly, the hippocampus, a region prominently affected by AD, demonstrated no GMV reductions in our study. Although other regions implicated in AD pathology did exhibit GMV reductions, such as the insula, amygdala, and caudate nuclei. Finally, a BrainMap meta-analysis of task-activation functional studies of the neural signature of MetS gray matter atrophy...
mask revealed significant associations with regions involved in cognitive reasoning, emotional valence, and reward perception.

4.1 | Cerebellum

Decreased GMV in the posterior cerebellum was the most significant and consistent regional difference in MetS across all age groups. The effects of decreased cerebellar GMV tend to vary depending on the cerebellar subregion where differences are seen. For instance, a commonly cited cause of cerebellar damage is alcohol dependence. Previous VBM studies have identified GMV in the vermis and anterior cerebellar regions—regions known to be involved in motor control and coordination—as significantly lower in alcoholics versus nonalcoholics (Mechtcheriakov et al., 2007). In contrast, atrophy in the posterior region of the cerebellum is attributed to “slowness,” defined as slow reaction time and walking speed (Chen et al., 2015). The effects of posterior cerebellar degeneration have been further supported by functional studies demonstrating that cortical regions significantly co-activating with the anterior cerebellum are the association motor areas and those most significantly co-activating with posterior cerebellum are regions implicated in cognition (Riedel et al., 2015). Furthermore, lesion studies investigating the effects of regional damage to the posterior cerebellum have identified deficits in executive function, visual spatial processing, linguistic skills, and regulation of affect (Schmahmann, 2004).

4.2 | Brainstem

Our study demonstrated significant MetS-associated decreased GMV in the pons and periaqueductual gray (PAG) regions of the brainstem. Human studies have shown that increased hemoglobin A1c, another blood glucose measure, is independently associated with the severity and prognosis of brainstem infarcts, primarily involving the pons (Li et al., 2012). Decreased activity in the PAG is associated with increased levels of pain (migraine-like headaches, fibromyalgia, nonspecific back pain) and anxiety. Animal studies have also found that diabetes-related neuropathic pain is associated with a decrease in functional activity of the PAG (Paulson, Wiley, & Morrow, 2007). Of note, forebrain projections to the PAG arise predominantly from the prefrontal cortex, insular cortex, and amygdala (Linnman, Moulton, Barmettler, Becerra, & Borsook, 2012), structures implicated in our study’s neural signature of MetS. PAG atrophy can thus serve as a potential neuroimaging biomarker responsible for increased levels of generalized pain symptoms in MetS patients.

4.3 | The appetitive network

Regions in the appetitive network are involved in appetite-related behaviors such as craving, feeding, and satiety. It consists of the lateral
hypothalamus and the reward circuit, which includes the OFC, caudate, insula, amygdala, nucleus accumbens, substantia nigra, and ventral tegmentum (Kenny, 2011). Hyperactivation of the appetitive network has been hypothesized to lead to overeating and obesity. Individuals with high trait reward sensitivity have demonstrated increased neural activity in the appetitive network when exposed to highly palatable foods such as pizza and chocolate cake (Beaver et al., 2006), including obese patients (Rothemund et al., 2007). As weight increases, deficits in the brain’s appetitive network emerge. For example, deficits in the caudate nuclei have led researchers to speculate that partial reward hypo-sensitivity may perpetuate the overconsumption of palatable foods as a compensatory mechanism for reward deficits (Kenny, 2011). As the motivation to consume palatable food increases, the hedonic value from the consumption of such foods decreases. These observations could have broader implications for neurocognitive functioning in other behavioral-cognitive domains involving overlapping brain structures (Cornier, 2011).

The OFC is an integral part of the cognitive processes related to decision-making, emotion valuation, and reward perception. This region also comprises the secondary taste cortex, a region responsible for the representation of the reward value of taste (Price, 2007). Furthermore, dysfunction in the OFC has been attributed to the overconsumption of food in obese patients (Cameron, Chaput, Sjödin, & Goldfield, 2017).

The caudate nuclei are involved in the modulation of inhibitory control, goal-directed actions, and procedural learning. Reduced activity in the caudate nucleus is associated with obesity in older adults (Green, Jacobson, Haase, & Murphy, 2011). Additionally, adolescents with T2DM have been found to exhibit reduced GMV in the caudate nuclei compared to metabolically healthy age- and weight-matched controls (Nouwen et al., 2017).

The insular cortex is predominantly associated with emotion, empathy, self-awareness, and interoception. It also processes information related to the hedonic valuation and taste of food (Small, 2010). The right insula in particular, has previously been reported to show GMV loss in MetS after correcting for allostatic load (Zsoldos et al., 2018).

The amygdala lends affective significance to perceived stimuli and enhances memory for emotionally-relevant stimuli. Its activity increases in response to hunger, particularly when exposed to high-calorie palatable food (Goldstone et al., 2009). FDG-PET studies show that increased levels of circulating insulin are correlated with decreased activity in the right amygdala and cerebellar vermis relative to whole brain, possibly explaining an individual’s impaired emotional response to high-calorie food (Anthony et al., 2006).
4.4 | Relation to AD, HD, and schizophrenia

The incidence and progression of AD is thought to be influenced by metabolic diseases, dysregulations, and comorbidities (Stranahan, 2015). In the Rotterdam Study (the first study to propose this link) T2DM was associated with a twofold increased risk of developing AD and all-type dementia (Ott et al., 1996). An association that has since been replicated in more recent studies (Arvanitakis, Wilson, Bienias, Evans, & Bennett, 2004; Chatterjee & Mudher, 2018). In our study we found a modest relationship between the MetS neural signature and that of AD, as shown in the BrainMap VBM meta-analysis. This is a relationship that conspicuously does not include the hippocampus. MetS, obesity, HTN, dyslipidemia and T2DM all are associated with an increased risk of developing AD and other dementias. However, the reverse could also be true; for instance, that neurodegeneration contributes to the development of metabolic disease (Biessels & Rea- gan, 2015). Therefore, although AD may moderately correlate with MetS, we consider our findings to only weakly support the relationship. We speculate that it is possible that AD-like symptoms are exhibited by certain individuals with MetS because of overlapping structural involvement, yet do not reflect the same underlying pathophysiological mechanism.

HD is a heritable neurodegenerative disease implicating the basal ganglia and cerebral cortex. Patients in advanced states of the disease are known to exhibit poor glycemic control and progressive weight loss (Aziz, Swaab, Pijl, & Roos, 2007). However, research within the past decade has shed light on the role that obesity-induced inflammation can play in the pathogenesis of HD. For instance, it has been demonstrated that insulin resistance and decreased circulating insulin-like growth factor 1 (IGF-1) can accelerate HD onset in individuals with the genetic predisposition (Lalic et al., 2008). Furthermore, mouse models have also indicated that mutations in the huntingtin gene expressed in the hypothalamus may be the causal factor for metabolic abnormalities seen in the disease, such as: impaired glucose metabolism, insulin resistance, and leptin resistance (Hult et al., 2011; Procaccini et al., 2016).

Schizophrenia is a neuropsychiatric disorder in which patients exhibit dysfunctions in language, behavior and affect, often in the form of delusions, hallucinations, and disorganized speech that tend to present in early adulthood. Among neuropsychiatric disorders, the association between schizophrenia and obesity is well documented (Saha, Chant, & McGrath, 2007). Moreover, a commonly cited association between schizophrenia and metabolic syndrome is thought to be treatment-emergent. A number of second-generation anti-psychotic drugs, most notably olanzapine, have been shown to cause weight gain, metabolic syndrome, and T2DM. It is thought that olanzapine’s appetite-stimulating effects via its antagonistic actions on the serotonin 5-HT2C and dopamine D2 receptors contribute to its metabolic disease side-effects (Patel et al., 2009). One key limitation for the BrainMap VBM database is its absence of flags indicating whether patient populations in VBM analyses suffer from metabolic comorbidities such as metabolic syndrome or obesity. We believe that schizophrenic patients on antipsychotics such as olanzapine might be weighing VBM effects related to MetS. However, more evidence is needed to support this speculation.

4.5 | Mechanisms of atrophy

Trophic effects associated with gray matter have been attributed to four primary mechanisms: transneuronal spread, nodal stress, trophic failure, and shared vulnerability (Zhou, Gennatas, Kramer, Miller, & Seeley, 2012). We believe that trophic failure, involving the subcellular dysfunction of trophic factors such as insulin, insulin-like growth factor, and leptin, is a likely mechanism for explaining our findings that is worth exploring (Verdile, Fuller, & Martins, 2015). When trophic factor expression and regulation is impaired, trophic failure in the form of poor cellular and synaptic maintenance hinders gray matter structural integrity (Fornito, Zalesky, & Breakspear, 2015). Shared vulnerability is also a likely candidate since similar neuronal cell types can be the targets of disease-specific changes due to shared genetic and metabolic profiles (Cioli, Abdì, Beaton, Burnod, & Mesmoudi, 2014). For example, animal models of obesity and wild-type mice fed high fat diets have found associations with dopamine-dependent mesocorticolimbic-prefrontal alterations which could impact reward learning, motivation, and executive functions (Stoeckel et al., 2016). In summary, a number of potential mechanisms emerging in the periphery that disturb the normal neurophysiological processes in gray matter can, collectively, be used to explain our reported findings.

4.6 | Limitations

The criteria used to describe the metabolically healthy and MetS groups were a mixture of the IDF and NCEP-ATP III classification systems with the notable absence of BP values in 57.4% of our samples. Although this limitation was addressed using sophisticated statistical methods involving available observations and related biometric data, the absence of directly measured BP values stands as a limitation. The nature of our choice for defining metabolically healthy controls and MetS participants as meeting a composite score of IDF and NCEP-ATP III criteria may differ from criteria used in other studies, especially in different ethnic populations. Importantly, the criteria chosen to define our samples was optimized for the dataset available.

This study focused on identifying GMV differences associated with MetS. The pattern identified moderately correlates to neurodegenerative diseases involving gray matter as HD, AD, and schizophrenia. Microinfarcts and other vascular-related events are also known to play a role in the pathophysiology of neurodegeneration (e.g., blood-brain barrier breakdown, white matter lesions, and inflammation; Stranahan, 2015). Given the strong evidence for small vessel disease in the comorbidities of MetS, it could be argued that white matter integrity is also an important parameter to investigate (Van Bloemenendaal et al., 2016), and we agree. However, an important part of the present study was to establish a link to cognition. White matter integrity as assessed by various imaging modalities does not predict cognitive status as well as gray matter (Lansley, Mataix-Cols, Grau, WILEY
Radua, & Sastre-Garriga, 2013). Nevertheless, a subsequent investigative report addressing white matter involvement in MetS is underway.

Sex-based differences in BMI-related responses to food cues, identified using functional MRI, indicate the presence of significant regional differences in brain activity between males and females (Atalayer et al., 2014; Cornier, Salzberg, Endly, Bessesen, & Tregellas, 2010). Although studies have shown that individuals with MetS exhibit worse cognitive performance with increasing number and severity of MetS components (Yaffe et al., 2004; Cavalieri et al., 2010), no study to our knowledge has demonstrated that gender differences are related to reduced GMV in MetS or T2DM.

The association between MetS, T2DM, obesity, and cognition has been well-characterized using psychometric evaluations (Yates et al., 2012). In this study, we demonstrated that regions associated with MetS also are related to cognition, supporting reports from the literature that link peripheral metabolic dysfunction to impaired emotion salience and cognition (Cameron et al., 2017). Nevertheless, we did not probe psychometric scores available to us in in the GOBS dataset on a per-subject level. For the purposes of this study, we ensured that participants were nondemented and did not differ in level of educational attainment.

Finally, we intentionally chose to use a cohort of geographically and ethno-culturally homogenous Mexican-Americans from an extended pedigree due to the genetic and environmental predisposition for developing MetS in this population. However, in selecting these participants, we did not account for family or household effects. We encourage others to reproduce our findings in other ethnocultural populations.

5 CONCLUSION
We report that MetS is associated with reduced GMV, a finding that is amplified with age. Gray matter regions associated with MetS include the posterior cerebellum, brainstem, and regions involved in the appetitive network such as the orbitofrontal cortex, caudate, amygdala and insula. Functionally, these regions were identified to correlate with reward perception, reasoning and emotional valence. Patterns of atrophy also indicated similarities to those seen in AD, but failed to recapitulate its most important features, namely hippocampal involvement.

ACKNOWLEDGMENTS
The authors thank Drs. Amy Garret, Tom Vanasse, and Cheasequeah Blevins for their valuable edits and insight, and the UT Health San Antonio Medical Scientist Training Program for their institutional and academic support. This study was supported by funds from the National Institutes of Health (NIH South Texas Medical Scientist Training Program: T32GM113898, NIMH: R01MH074457-11S1, NCATS Translational Scientist Training Program: TL1TR002647-01.) The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

CONFLICT OF INTEREST
The authors declare no potential conflict of interest.

AUTHOR CONTRIBUTIONS
Eithan Kotkowski and Peter Fox devised the project and its main conceptual ideas with help from Ralph DeFronzo. Eithan Kotkowski wrote the manuscript with support from Peter Fox, Ralph DeFronzo, Crystal Franklin, and David Glahn. Crystal Franklin was instrumental in the design of the methods involving data curation and image processing with help from Maximino Salazar. Larry Price assisted in the design of statistical methods and analyses used in the study. Mary Woolsey, John Blangero, David Glahn, and Peter Fox obtained the individual subject data and MRI scans used in this study.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from Drs. David Glahn and John Blangero. Restrictions apply to the availability of these data, which were used under license for this study. Data are available from the authors with the permission of Drs. David Glahn and John Blangero.

REFERENCES


Additional supporting information may be found online in the Supporting Information section at the end of this article.